Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Mirum Pharmaceuticals, Inc. (MIRM)
USD119.43
+0.39 (+0.32%)
US NASDAQ Healthcare Biotechnology
Address
950 Tower Lane 94404
Foster City, CA, US
Foster City, CA, US
CEO
Christopher Peetz
Website
mirumpharma.com
IPO
2019-07-18
CIK 1759425 ISIN US6047491013
Description
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD119.43
+0.39 (+0.32%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
992.8K
Beta
0.51
Float Shares
50.07M
Free Float %
99.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.67% | +2.84% | +10.77% | +3.67% | +54.34% | +35.31% | +136.09% | +310.60% | +512.49% | +709.08% | +709.08% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (18 ratings, all time)
Buy
Price Targets & DCF
Current price
119.43
Low
118.00
-1.2%
Consensus
142.30
+19.2%
Median
139.00
+16.4%
High
185.00
+54.9%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 8 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 4 |
144.25
+20.8%
|
| Last Quarter | 8 |
134.88
+12.9%
|
| Last Year | 25 |
111.44
-6.7%
|
| All Time | 39 |
91.21
-23.6%
|
Quality scores
Altman Z-Score
3.49
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+54.7% ★ Q1'26: +43.3% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+74.6% ★ Q1'26: -4,376.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-3.8% Q1'26: -143.5% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-1.4% Q1'26: -39.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-2.8% ★ Q1'26: -140.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+5.6% Q1'26: +20.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×18.57× ★ Q1'26: -1.44× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 8 Rev. Ana. 6 EPS Ana. |
Dec 2027 8 Rev. Ana. 7 EPS Ana. |
Dec 2028 7 Rev. Ana. 7 EPS Ana. |
Dec 2029 3 Rev. Ana. 2 EPS Ana. |
Dec 2030 6 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 10.00M (-100.0%)
|
19.14M
est: 78.42M (-75.6%)
|
77.06M
est: 76.00M (+1.4%)
|
186.37M
est: 264.38M (-29.5%)
|
336.89M
est: 334.42M (+0.7%)
|
521.31M
est: 515.52M (+1.1%)
|
674.64M
671.97M – 681.46M
+30.9% YoY
|
813.17M
747.20M – 850.29M
+20.5% YoY
|
1.06B
1.06B – 1.06B
+30.3% YoY
|
1.37B
1.29B – 1.43B
+29.1% YoY
|
1.73B
1.62B – 1.80B
+26.2% YoY
|
| EBITDA |
-102.31M
est: -3.76M (-2,624.2%)
|
-65.39M
est: -29.45M (-122.0%)
|
-122.85M
est: -28.54M (-330.4%)
|
-136.49M
est: -150.41M (+9.3%)
|
-48.97M
est: -190.27M (+74.3%)
|
17.21M
est: -293.30M (+105.9%)
|
-383.83M
-387.71M – -382.31M
-30.9% YoY
|
-462.64M
-483.76M – -425.11M
-20.5% YoY
|
-602.78M
-602.78M – -602.78M
-30.3% YoY
|
-778.00M
-813.34M – -732.28M
-29.1% YoY
|
-981.67M
-1.03B – -923.99M
-26.2% YoY
|
| EBIT |
-102.93M
est: -4.01M (-2,465.6%)
|
-66.36M
est: -31.46M (-110.9%)
|
-126.09M
est: -30.49M (-313.5%)
|
-147.32M
est: -159.65M (+7.7%)
|
-72.60M
est: -201.96M (+64.1%)
|
-7.04M
est: -311.32M (+97.7%)
|
-407.41M
-411.53M – -405.80M
-30.9% YoY
|
-491.06M
-513.48M – -451.23M
-20.5% YoY
|
-639.81M
-639.81M – -639.80M
-30.3% YoY
|
-825.79M
-863.30M – -777.26M
-29.1% YoY
|
-1.04B
-1.09B – -980.74M
-26.2% YoY
|
| Net Income |
-103.27M
est: -159.42M (+35.2%)
|
-83.99M
est: -212.97M (+60.6%)
|
-135.67M
est: -191.71M (+29.2%)
|
-163.42M
est: -119.45M (-36.8%)
|
-87.94M
est: -58.56M (-50.2%)
|
-23.36M
est: -13.72M (-70.3%)
|
-921.58M
-1.20B – -96.03M
-6,618.4% YoY
|
11.84M
-178.35M – 92.57M
+101.3% YoY
|
175.27M
31.62M – 286.13M
+1,380.7% YoY
|
272.07M
251.29M – 288.14M
+55.2% YoY
|
439.03M
405.50M – 464.96M
+61.4% YoY
|
| SGA |
22.69M
est: 13.27M (+71.0%)
|
59.22M
est: 104.04M (-43.1%)
|
89.07M
est: 100.82M (-11.7%)
|
145.88M
est: 323.92M (-55.0%)
|
202.22M
est: 409.75M (-50.6%)
|
257.03M
est: 631.63M (-59.3%)
|
826.59M
823.32M – 834.95M
+30.9% YoY
|
996.32M
915.49M – 1.04B
+20.5% YoY
|
1.30B
1.30B – 1.30B
+30.3% YoY
|
1.68B
1.58B – 1.75B
+29.1% YoY
|
2.11B
1.99B – 2.21B
+26.2% YoY
|
| EPS |
-4.09
est: -3.35 (-21.9%)
|
-2.77
est: -4.48 (+38.2%)
|
-4.01
est: -4.03 (+0.6%)
|
-4.00
est: -2.40 (-66.6%)
|
-1.85
est: -1.61 (-14.7%)
|
-0.47
est: -0.25 (-90.8%)
|
-15.47
-23.84 – -1.91
-6,182.3% YoY
|
-0.30
-3.55 – 1.84
+98.0% YoY
|
2.52
0.63 – 5.70
+927.5% YoY
|
5.42
5.01 – 5.74
+115.1% YoY
|
8.75
8.08 – 9.26
+61.4% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-05 | Morgan Stanley | Overweight | Overweight | Maintain |
| 2026-05-04 | HC Wainwright & Co. | Buy | Buy | Maintain |
| 2026-04-29 | Stifel | Buy | Buy | Maintain |
| 2026-04-28 | Baird | Outperform | Outperform | Maintain |
| 2026-04-27 | HC Wainwright & Co. | Buy | Buy | Maintain |
| 2026-04-21 | Citizens | Market Outperform | Market Outperform | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-171.92M
OE per share TTM
-2.84
Owner's Yield
-2.65%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
2.1%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
60
Total invested
185.11M
Insider transactions (90d)
0
Beneficial owners (>5%)
31
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EIN #00-0000000 | 4.99M | 10.60% | — | 4.99M | — | 4.99M | IA, HC | Jersey, Channel Islands | 2024-07-10 | ↗ |
| 2 | BVF Inc. | 4.37M | 9.40% | — | — | — | 4.37M | CO | Delaware | 2023-09-18 | ↗ |
| 3 | BVF Partners L.P. | 4.37M | 9.40% | — | — | — | 4.37M | IA, PN | Delaware | 2023-09-18 | ↗ |
| 4 | Mark N. Lampert | 4.37M | 9.40% | — | — | — | 4.37M | IN | Delaware | 2023-09-18 | ↗ |
| 5 | BVF GP Holdings LLC | 4.10M | 8.90% | — | — | — | 4.10M | OO | Delaware | 2023-09-18 | ↗ |
| 6 | (1) BlackRock, Inc. | 3.37M | 7.10% | — | — | 3.37M | — | HC | Delaware | 2024-10-22 | ↗ |
| 7 | Company, L.P. | 3.28M | 10.72% | — | 3.28M | — | — | PN | Delaware | 2022-02-11 | ↗ |
| 8 | The Vanguard Group - 23-1945930 | 2.48M | 5.31% | — | 46.5K | — | — | IA | Pennsylvania | 2024-02-13 | ↗ |
| 9 | BVF I GP LLC | 2.33M | 5.00% | — | — | — | 2.33M | OO | Delaware | 2023-09-18 | ↗ |
| 10 | Biotechnology Value Fund, L.P. | 2.33M | 5.00% | — | — | — | 2.33M | PN | Delaware | 2023-09-18 | ↗ |
| 11 | Eventide Asset Management, LLC | 2.06M | 5.60% | 2.06M | — | 2.06M | — | IA | Delaware | 2023-02-14 | ↗ |
| 12 | Finny Kuruvilla, M.D. Ph. D. | 2.06M | 5.60% | — | 2.06M | — | — | HC, IN | United States | 2023-02-14 | ↗ |
| 13 | Robin C. John | 2.06M | 5.60% | — | 2.06M | — | — | HC, IN | United States | 2023-02-14 | ↗ |
| 14 | Deerfield Management Company, L.P. | 2.03M | 5.53% | — | 2.03M | — | — | PN | Delaware | 2022-09-12 | ↗ |
| 15 | James E. Flynn | 2.03M | 5.53% | — | 2.03M | — | — | IN | Delaware | 2022-09-12 | ↗ |
| 16 | Takeda Pharmaceutical Company Limited | 1.86M | 7.20% | — | 1.86M | — | — | CO | — | 2021-01-27 | ↗ |
| 17 | Takeda Pharmaceuticals U.S.A., Inc. | 1.86M | 7.20% | — | 1.86M | — | — | CO | — | 2021-01-27 | ↗ |
| 18 | BVF II GP LLC | 1.77M | 3.80% | — | — | — | 1.77M | OO | Delaware | 2023-09-18 | ↗ |
| 19 | Biotechnology Value Fund II, L.P. | 1.77M | 3.80% | — | — | — | 1.77M | PN | Delaware | 2023-09-18 | ↗ |
| 20 | Rock Springs Capital LLC | 1.54M | 5.02% | — | 1.54M | — | — | HC, OO | Delaware | 2022-02-15 | ↗ |
| 21 | Rock Springs Capital Management LP | 1.54M | 5.02% | — | 1.54M | — | — | IA | Delaware | 2022-02-15 | ↗ |
| 22 | Rock Springs Capital Master Fund LP | 1.45M | 4.73% | — | 1.45M | — | — | PN | Cayman Islands | 2022-02-15 | ↗ |
| 23 | Deerfield Mgmt IV, L.P. | 1.07M | 2.91% | — | 1.07M | — | — | PN | Delaware | 2022-09-12 | ↗ |
| 24 | Deerfield Private Design Fund IV, L.P. | 1.07M | 2.91% | — | 1.07M | — | — | PN | Delaware | 2022-09-12 | ↗ |
| 25 | Deerfield Healthcare Innovations Fund, L.P. | 964.8K | 2.63% | — | 964.8K | — | — | PN | Delaware | 2022-09-12 | ↗ |
| 26 | Deerfield Mgmt HIF, L.P. | 964.8K | 2.63% | — | 964.8K | — | — | PN | Delaware | 2022-09-12 | ↗ |
| 27 | BVF Partners OS Ltd. | 207.1K | 1.00% | — | — | — | 207.1K | CO | Delaware | 2023-09-18 | ↗ |
| 28 | Biotechnology Value Trading Fund OS LP | 207.1K | 1.00% | — | — | — | 207.1K | PN | Delaware | 2023-09-18 | ↗ |
| 29 | Deerfield Mgmt, L.P. | — | 0.00% | — | — | — | — | PN | Delaware | 2022-02-11 | ↗ |
| 30 | Deerfield Special Situations Fund, L.P. | — | 0.00% | — | — | — | — | PN | Delaware | 2022-02-11 | ↗ |
| 31 | Shire International GmbH in Liquidation | — | 0.00% | — | — | — | — | CO | — | 2021-01-27 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
60
-225 vs prev Q
New positions
14
Closed positions
234
Increased
30
Reduced
20
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 421.8K +421.8K (+100.0%) | 33.32B +33.3B (+100.0%) | 0.73% +0.726 pp | 0.05% +0.050 pp | USD78.99 +0.0% | 1 qtrs NEW |
| 2 | FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 6.80M +— (+0.0%) | 536.75M +38.6M (+7.7%) | 11.70% +0.000 pp | 14.42% -0.510 pp | USD26.20 +201.5% | 16 qtrs — |
| 3 | JANUS HENDERSON GROUP PLC | 6.07M +1.1M (+21.4%) | 479.05M +112.5M (+30.7%) | 10.44% +1.838 pp | 0.21% +0.047 pp | USD41.84 +88.8% | 12 qtrs — |
| 4 | BLACKROCK, INC. | 3.65M +42.9K (+1.2%) | 287.94M +23.8M (+9.0%) | 6.27% +0.074 pp | 0.00% +0.000 pp | USD40.53 +94.9% | 6 qtrs — |
| 5 | VANGUARD GROUP INC | 2.60M +50.7K (+2.0%) | 205.07M +18.5M (+9.9%) | 4.47% +0.087 pp | 0.00% +0.000 pp | USD26.98 +192.8% | 26 qtrs — |
| 6 | STATE STREET CORP | 2.14M +797.1K (+59.2%) | 169.35M +70.6M (+71.5%) | 3.69% +1.372 pp | 0.01% +0.002 pp | USD46.72 +69.1% | 26 qtrs — |
| 7 | EVENTIDE ASSET MANAGEMENT, LLC | 2.09M -429.0K (-17.0%) | 165.37M -19.6M (-10.6%) | 3.60% -0.738 pp | 2.58% -0.457 pp | USD26.05 +203.2% | 14 qtrs — |
| 8 | BVF INC/IL | 1.50M +— (+0.0%) | 118.11M +8.5M (+7.7%) | 2.57% +0.000 pp | 3.98% -0.468 pp | USD31.60 +150.0% | 10 qtrs — |
| 9 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.42M +137.1K (+10.7%) | 112.20M +18.1M (+19.3%) | 2.44% +0.236 pp | 0.01% +0.002 pp | USD34.97 +125.9% | 14 qtrs — |
| 10 | NOVO HOLDINGS A/S | 1.26M +— (+0.0%) | 99.85M +7.2M (+7.7%) | 2.18% +0.000 pp | 7.75% +1.782 pp | USD10.06 +685.2% | 26 qtrs — |
| 11 | WELLINGTON MANAGEMENT GROUP LLP | 1.24M +447.1K (+56.6%) | 97.78M +39.8M (+68.7%) | 2.13% +0.770 pp | 0.02% +0.007 pp | USD71.40 +10.6% | 8 qtrs — |
| 12 | TANG CAPITAL MANAGEMENT LLC | 1.24M +— (+0.0%) | 97.63M +7.0M (+7.7%) | 2.13% +0.000 pp | 4.82% +1.335 pp | USD21.44 +268.4% | 15 qtrs — |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 1.06M +52.9K (+5.2%) | 83.98M +9.9M (+13.4%) | 1.83% +0.091 pp | 0.01% +0.001 pp | USD30.70 +157.3% | 26 qtrs — |
| 14 | D. E. SHAW & CO., INC. | 948.2K +24.7K (+2.7%) | 74.90M +7.2M (+10.6%) | 1.63% +0.042 pp | 0.04% +0.003 pp | USD56.38 +40.1% | 5 qtrs — |
| 15 | CLEARBRIDGE INVESTMENTS, LLC | 866.0K -137.8K (-13.7%) | 68.40M -5.2M (-7.0%) | 1.49% -0.237 pp | 0.05% -0.001 pp | USD35.43 +122.9% | 16 qtrs — |
| 16 | CITADEL ADVISORS LLC | 840.2K -200.3K (-19.3%) | 66.37M -9.9M (-13.0%) | 1.45% -0.345 pp | 0.01% -0.002 pp | USD25.23 +213.1% | 18 qtrs — |
| 17 | POLAR CAPITAL HOLDINGS PLC | 793.6K -26.9K (-3.3%) | 62.69M +2.5M (+4.2%) | 1.37% -0.046 pp | 0.24% -0.047 pp | USD33.78 +133.8% | 16 qtrs — |
| 18 | ROCK SPRINGS CAPITAL MANAGEMENT LP | 762.3K +1.2K (+0.2%) | 60.21M +4.4M (+7.9%) | 1.31% +0.002 pp | 3.09% -0.173 pp | USD17.08 +362.5% | 26 qtrs — |
| 19 | GOLDMAN SACHS GROUP INC | 724.3K +273.5K (+60.7%) | 57.21M +24.2M (+73.1%) | 1.25% +0.471 pp | 0.01% +0.003 pp | USD49.35 +60.1% | 17 qtrs — |
| 20 | BANK OF AMERICA CORP /DE/ | 713.5K +323.0K (+82.7%) | 56.36M +27.7M (+96.9%) | 1.23% +0.443 pp | 0.00% +0.002 pp | USD52.26 +51.1% | 26 qtrs — |
| 21 | BNP PARIBAS ARBITRAGE, SNC | 655.8K +54.7K (+9.1%) | 51.80M +7.7M (+17.6%) | 1.13% +0.094 pp | 0.02% 0.000 pp | USD51.61 +53.1% | 5 qtrs — |
| 22 | FRANKLIN RESOURCES INC | 650.7K +49.6K (+8.2%) | 51.40M +7.3M (+16.6%) | 1.12% +0.085 pp | 0.01% +0.002 pp | USD29.58 +167.0% | 17 qtrs — |
| 23 | FMR LLC | 646.5K +6.2K (+1.0%) | 51.06M +4.1M (+8.8%) | 1.11% +0.011 pp | 0.00% +0.000 pp | USD70.77 +11.6% | 16 qtrs — |
| 24 | LORD, ABBETT & CO. LLC | 580.0K -82.0K (-12.4%) | 45.81M -2.7M (-5.6%) | 1.00% -0.141 pp | 0.14% -0.004 pp | USD39.35 +100.7% | 6 qtrs — |
| 25 | PICTET ASSET MANAGEMENT HOLDING SA | 577.3K +36.0K (+6.7%) | 45.60M +5.9M (+14.9%) | 0.99% +0.062 pp | 0.04% +0.006 pp | USD33.65 +134.7% | 10 qtrs — |
| 26 | SOLEUS CAPITAL MANAGEMENT, L.P. | 573.6K +424.9K (+285.8%) | 45.31M +34.4M (+315.7%) | 0.99% +0.731 pp | 1.67% +1.123 pp | USD71.71 +10.2% | 3 qtrs — |
| 27 | CANDRIAM S.C.A. | 569.6K +166.6K (+41.3%) | 44.99M +15.4M (+52.3%) | 0.98% +0.287 pp | 0.22% +0.069 pp | USD49.33 +60.1% | 7 qtrs — |
| 28 | WOODLINE PARTNERS LP | 567.9K +— (+0.0%) | 44.86M +3.2M (+7.7%) | 0.98% +0.000 pp | 0.17% -0.022 pp | USD35.90 +120.0% | 14 qtrs — |
| 29 | BANK OF NEW YORK MELLON CORP | 565.6K +120.1K (+26.9%) | 44.68M +12.0M (+36.8%) | 0.97% +0.207 pp | 0.01% +0.002 pp | USD51.15 +54.4% | 25 qtrs — |
| 30 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 521.7K +25.7K (+5.2%) | 41.21M +4.8M (+13.3%) | 0.90% +0.044 pp | 0.11% -0.007 pp | USD49.40 +59.9% | 11 qtrs — |
| 31 | LOOMIS SAYLES & CO L P | 515.0K -24.1K (-4.5%) | 40.68M +1.2M (+2.9%) | 0.89% -0.041 pp | 0.05% +0.002 pp | USD39.32 +100.9% | 6 qtrs — |
| 32 | NUVEEN, LLC | 503.0K -98.6K (-16.4%) | 39.74M -4.4M (-9.9%) | 0.87% -0.170 pp | 0.01% -0.001 pp | USD45.59 +73.3% | 4 qtrs — |
| 33 | FEDERATED HERMES, INC. | 482.0K +135.4K (+39.1%) | 38.07M +12.7M (+49.9%) | 0.83% +0.233 pp | 0.06% +0.019 pp | USD54.57 +44.7% | 16 qtrs — |
| 34 | FIRST TURN MANAGEMENT, LLC | 481.6K -89.0K (-15.6%) | 38.04M -3.8M (-9.1%) | 0.83% -0.153 pp | 4.35% -1.934 pp | USD33.28 +137.3% | 9 qtrs — |
| 35 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 467.5K -30.0K (-6.0%) | 36.93M +455.9K (+1.3%) | 0.80% -0.052 pp | 0.06% -0.002 pp | USD57.62 +37.1% | 10 qtrs — |
| 36 | RENAISSANCE TECHNOLOGIES LLC | 439.1K -74.4K (-14.5%) | 34.68M -3.0M (-7.9%) | 0.76% -0.128 pp | 0.05% +0.004 pp | USD52.85 +49.5% | 6 qtrs — |
| 37 | MORGAN STANLEY | 425.7K -244.5K (-36.5%) | 33.62M -15.5M (-31.6%) | 0.73% -0.421 pp | 0.00% -0.001 pp | USD38.74 +103.9% | 26 qtrs — |
| 38 | BOONE CAPITAL MANAGEMENT LLC | 421.2K -114.5K (-21.4%) | 33.27M -6.0M (-15.3%) | 0.73% -0.197 pp | 10.44% -2.435 pp | USD33.99 +132.4% | 10 qtrs — |
| 39 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 409.3K +14.8K (+3.8%) | 32.33M +3.4M (+11.8%) | 0.70% +0.026 pp | 0.01% +0.000 pp | USD35.65 +121.6% | 24 qtrs — |
| 40 | TIMESSQUARE CAPITAL MANAGEMENT, LLC | 395.8K +95.2K (+31.7%) | 31.27M +9.2M (+41.9%) | 0.68% +0.164 pp | 0.47% +0.156 pp | USD74.68 +5.8% | 2 qtrs — |
| 41 | TWO SIGMA INVESTMENTS, LP | 388.5K +45.4K (+13.2%) | 30.69M +5.5M (+22.0%) | 0.67% +0.078 pp | 0.04% +0.006 pp | USD57.48 +37.4% | 11 qtrs — |
| 42 | NORTHERN TRUST CORP | 374.9K -10.5K (-2.7%) | 29.61M +1.4M (+4.8%) | 0.65% -0.018 pp | 0.00% +0.000 pp | USD26.99 +192.7% | 26 qtrs — |
| 43 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 372.5K -239.8K (-39.2%) | 29.42M -15.5M (-34.5%) | 0.64% -0.413 pp | 0.02% -0.011 pp | USD70.54 +12.0% | 3 qtrs — |
| 44 | NEXT CENTURY GROWTH INVESTORS LLC | 368.0K +7.1K (+2.0%) | 29.07M +2.6M (+9.9%) | 0.63% +0.012 pp | 2.02% +0.090 pp | USD56.17 +40.6% | 6 qtrs — |
| 45 | EMERALD ADVISERS, LLC | 367.1K -2.5K (-0.7%) | 29.00M +1.9M (+7.0%) | 0.63% -0.004 pp | 0.89% +0.025 pp | USD54.76 +44.2% | 3 qtrs — |
| 46 | WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 336.7K +23.4K (+7.5%) | 26.60M +3.6M (+15.8%) | 0.58% +0.040 pp | 0.07% +0.015 pp | USD73.71 +7.2% | 2 qtrs — |
| 47 | UBS GROUP AG | 320.8K +44.9K (+16.3%) | 25.34M +5.1M (+25.3%) | 0.55% +0.077 pp | 0.00% +0.001 pp | USD54.40 +45.2% | 14 qtrs — |
| 48 | PATIENT SQUARE CAPITAL LP | 298.7K +194.4K (+186.5%) | 23.59M +15.9M (+208.7%) | 0.51% +0.335 pp | 5.05% +3.006 pp | USD66.42 +18.9% | 5 qtrs — |
| 49 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 298.0K -91.6K (-23.5%) | 23.54M -5.0M (-17.6%) | 0.51% -0.158 pp | 0.08% -0.013 pp | USD71.76 +10.1% | 6 qtrs — |
| 50 | BALYASNY ASSET MANAGEMENT L.P. | 285.9K -31.3K (-9.9%) | 22.58M -669.4K (-2.9%) | 0.49% -0.054 pp | 0.03% -0.001 pp | USD73.31 +7.7% | 5 qtrs — |
| 51 | PENN CAPITAL MANAGEMENT COMPANY, LLC | 281.9K -26.1K (-8.5%) | 22.32M -309.0K (-1.4%) | 0.49% -0.045 pp | 1.78% +0.040 pp | USD33.00 +139.4% | 11 qtrs — |
| 52 | HOOD RIVER CAPITAL MANAGEMENT LLC | 280.0K +280.0K (+100.0%) | 22.12M +22.1M (+100.0%) | 0.48% +0.482 pp | 0.24% +0.243 pp | USD78.99 +0.0% | 1 qtrs NEW |
| 53 | AMERIPRISE FINANCIAL INC | 271.5K +68.4K (+33.7%) | 21.44M +6.6M (+44.0%) | 0.47% +0.118 pp | 0.00% +0.001 pp | USD50.36 +56.9% | 12 qtrs — |
| 54 | NORGES BANK | 263.2K +263.2K (+100.0%) | 20.79M +20.8M (+100.0%) | 0.45% +0.453 pp | 0.00% +0.002 pp | USD78.99 +0.0% | 1 qtrs NEW |
| 55 | PERCEPTIVE ADVISORS LLC | 259.5K +259.5K (+100.0%) | 20.50M +20.5M (+100.0%) | 0.45% +0.447 pp | 0.37% +0.365 pp | USD78.99 +0.0% | 1 qtrs NEW |
| 56 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 257.2K +257.2K (+100.0%) | 20.32M +20.3M (+100.0%) | 0.44% +0.443 pp | 0.02% +0.023 pp | USD78.99 +0.0% | 3 qtrs — |
| 57 | ERSTE ASSET MANAGEMENT GMBH | 250.0K +— (+0.0%) | 19.78M +1.6M (+8.6%) | 0.43% +0.000 pp | 0.17% -0.010 pp | USD30.93 +155.4% | 10 qtrs — |
| 58 | RAYMOND JAMES FINANCIAL INC | 246.4K -5.3K (-2.1%) | 19.46M +1.0M (+5.5%) | 0.42% -0.009 pp | 0.01% +0.000 pp | USD41.88 +88.6% | 5 qtrs — |
| 59 | MILLENNIUM MANAGEMENT LLC | 244.3K -64.8K (-21.0%) | 19.30M -3.4M (-14.8%) | 0.42% -0.112 pp | 0.01% -0.002 pp | USD36.29 +117.7% | 12 qtrs — |
| 60 | EMERALD MUTUAL FUND ADVISERS TRUST | 242.3K +23.3K (+10.6%) | 19.14M +3.1M (+19.2%) | 0.42% +0.040 pp | 0.93% +0.103 pp | USD53.73 +47.0% | 3 qtrs — |
| 61 | TWO SIGMA ADVISERS, LP | 232.1K -44.3K (-16.0%) | 18.33M -1.9M (-9.5%) | 0.40% -0.076 pp | 0.04% -0.005 pp | USD48.54 +62.7% | 21 qtrs — |
| 62 | NAN FUNG TRINITY (HK) LTD | 227.5K +71.2K (+45.6%) | 17.97M +6.5M (+56.9%) | 0.39% +0.123 pp | 1.42% +0.280 pp | USD60.62 +30.3% | 3 qtrs — |
| 63 | LOGOS GLOBAL MANAGEMENT LP | 225.0K +225.0K (+100.0%) | 17.77M +17.8M (+100.0%) | 0.39% +0.387 pp | 1.07% +1.074 pp | USD78.99 +0.0% | 1 qtrs NEW |
| 64 | NEW YORK STATE COMMON RETIREMENT FUND | 217.6K -25.8K (-10.6%) | 17.19M -654.0K (-3.7%) | 0.37% -0.044 pp | 0.02% 0.000 pp | USD30.15 +162.0% | 26 qtrs — |
| 65 | HANDELSBANKEN FONDER AB | 213.5K +213.5K (+100.0%) | 16.86M +16.9M (+100.0%) | 0.37% +0.368 pp | 0.05% +0.051 pp | USD78.99 +0.0% | 1 qtrs NEW |
| 66 | NICHOLAS INVESTMENT PARTNERS, LP | 213.4K -3.7K (-1.7%) | 16.86M +942.5K (+5.9%) | 0.37% -0.006 pp | 1.23% +0.011 pp | USD45.50 +73.6% | 11 qtrs — |
| 67 | RUSSELL INVESTMENTS GROUP, LTD. | 209.2K -69.6K (-25.0%) | 16.52M -3.9M (-19.1%) | 0.36% -0.120 pp | 0.02% -0.005 pp | USD46.95 +68.2% | 19 qtrs — |
| 68 | POINT72 ASSET MANAGEMENT, L.P. | 190.6K -600.0K (-75.9%) | 15.06M -42.9M (-74.0%) | 0.33% -1.033 pp | 0.02% -0.080 pp | USD64.26 +22.9% | 4 qtrs — |
| 69 | DEUTSCHE BANK AG\ | 186.7K +2.4K (+1.3%) | 14.75M +1.2M (+9.1%) | 0.32% +0.004 pp | 0.00% +0.000 pp | USD40.39 +95.6% | 26 qtrs — |
| 70 | SEGALL BRYANT & HAMILL, LLC | 185.0K +185.0K (+100.0%) | 14.62M +14.6M (+100.0%) | 0.32% +0.319 pp | 0.20% +0.198 pp | USD78.99 +0.0% | 1 qtrs NEW |
| 71 | ALGERT GLOBAL LLC | 174.2K -16.4K (-8.6%) | 13.76M -214.0K (-1.5%) | 0.30% -0.028 pp | 0.21% -0.019 pp | USD51.22 +54.2% | 5 qtrs — |
| 72 | VOLEON CAPITAL MANAGEMENT LP | 173.1K +86.5K (+100.0%) | 13.67M +7.3M (+115.5%) | 0.30% +0.149 pp | 0.29% +0.139 pp | USD76.15 +3.7% | 2 qtrs — |
| 73 | SQUAREPOINT OPS LLC | 172.4K +44.5K (+34.8%) | 13.62M +4.2M (+45.3%) | 0.30% +0.077 pp | 0.01% +0.005 pp | USD71.53 +10.4% | 13 qtrs — |
| 74 | LEGAL & GENERAL GROUP PLC | 168.4K +1.2K (+0.7%) | 13.30M +1.0M (+8.5%) | 0.29% +0.002 pp | 0.00% +0.000 pp | USD62.26 +26.9% | 25 qtrs — |
| 75 | RICE HALL JAMES & ASSOCIATES, LLC | 164.4K -297.0 (-0.2%) | 12.99M +912.3K (+7.6%) | 0.28% -0.001 pp | 0.72% +0.057 pp | USD26.47 +198.4% | 12 qtrs — |
| 76 | PALO ALTO INVESTORS LP | 156.4K +91.7K (+141.8%) | 12.36M +7.6M (+160.5%) | 0.27% +0.158 pp | 1.72% +0.842 pp | USD52.91 +49.3% | 17 qtrs — |
| 77 | CITIGROUP INC | 146.0K -1.3K (-0.9%) | 11.53M +736.9K (+6.8%) | 0.25% -0.002 pp | 0.01% +0.000 pp | USD50.36 +56.9% | 26 qtrs — |
| 78 | PDT PARTNERS, LLC | 145.4K +— (+0.0%) | 11.48M +825.8K (+7.7%) | 0.25% +0.000 pp | 0.74% +0.073 pp | USD39.32 +100.9% | 7 qtrs — |
| 79 | BARCLAYS PLC | 142.1K -103.8K (-42.2%) | 11.23M +1.6M (+17.1%) | 0.24% -0.250 pp | 0.00% +0.000 pp | USD50.53 +56.3% | 16 qtrs — |
| 80 | FIRST TRUST ADVISORS LP | 137.7K -6.5K (-4.5%) | 10.88M +302.1K (+2.9%) | 0.24% -0.011 pp | 0.01% +0.000 pp | USD41.04 +92.5% | 8 qtrs — |
| 81 | ENSIGN PEAK ADVISORS, INC | 134.0K +— (+0.0%) | 10.58M +761.0K (+7.7%) | 0.23% +0.000 pp | 0.02% +0.003 pp | USD19.11 +313.3% | 25 qtrs — |
| 82 | HIGHLANDER PARTNERS, L.P. | 123.0K +— (+0.0%) | 9.71M +698.5K (+7.7%) | 0.21% +0.000 pp | 3.49% +0.341 pp | USD15.95 +395.2% | 17 qtrs — |
| 83 | WELLS FARGO & COMPANY/MN | 115.4K +88.4K (+326.5%) | 9.12M +7.1M (+359.6%) | 0.20% +0.152 pp | 0.00% +0.001 pp | USD71.83 +10.0% | 15 qtrs — |
| 84 | ESSEX INVESTMENT MANAGEMENT CO LLC | 111.3K -2.1K (-1.9%) | 8.79M +474.8K (+5.7%) | 0.19% -0.004 pp | 1.34% +0.068 pp | USD51.03 +54.8% | 3 qtrs — |
| 85 | QUBE RESEARCH & TECHNOLOGIES LTD | 109.0K +63.9K (+141.9%) | 8.61M +5.3M (+160.7%) | 0.19% +0.110 pp | 0.01% +0.005 pp | USD65.26 +21.0% | 4 qtrs — |
| 86 | RHENMAN & PARTNERS ASSET MANAGEMENT AB | 106.3K +50.0K (+88.9%) | 8.39M +4.3M (+103.5%) | 0.18% +0.086 pp | 0.78% +0.328 pp | USD52.09 +51.6% | 8 qtrs — |
| 87 | MARSHALL WACE, LLP | 102.7K +62.9K (+157.8%) | 8.11M +5.2M (+177.8%) | 0.18% +0.108 pp | 0.01% +0.004 pp | USD71.21 +10.9% | 8 qtrs — |
| 88 | HENNION & WALSH ASSET MANAGEMENT, INC. | 98.3K -17.6K (-15.2%) | 7.76M -729.0K (-8.6%) | 0.17% -0.030 pp | 0.27% -0.040 pp | USD33.50 +135.8% | 11 qtrs — |
| 89 | JPMORGAN CHASE & CO | 97.4K -2.8K (-2.8%) | 7.69M +346.2K (+4.7%) | 0.17% -0.034 pp | 0.00% +0.000 pp | USD44.70 +76.7% | 26 qtrs — |
| 90 | SILVERCREST ASSET MANAGEMENT GROUP LLC | 90.1K +— (+0.0%) | 7.11M +511.5K (+7.7%) | 0.16% +0.000 pp | 0.05% +0.005 pp | USD24.37 +224.1% | 17 qtrs — |
| 91 | HEALTHINVEST PARTNERS AB | 89.7K -3.9K (-4.2%) | 7.08M +6.4M (+872.4%) | 0.15% -0.007 pp | 2.26% -0.441 pp | USD36.97 +113.7% | 8 qtrs — |
| 92 | SWISS NATIONAL BANK | 74.3K +2.3K (+3.2%) | 5.87M +590.6K (+11.2%) | 0.13% +0.004 pp | 0.00% +0.000 pp | USD27.14 +191.0% | 15 qtrs — |
| 93 | RAFFERTY ASSET MANAGEMENT, LLC | 72.9K +39.8K (+120.2%) | 5.76M +3.3M (+137.3%) | 0.13% +0.069 pp | 0.02% +0.012 pp | USD56.50 +39.8% | 14 qtrs — |
| 94 | VICTORY CAPITAL MANAGEMENT INC | 72.2K +59.0K (+445.1%) | 5.70M +4.7M (+487.4%) | 0.12% +0.102 pp | 0.00% +0.003 pp | USD73.46 +7.5% | 4 qtrs — |
| 95 | VOYA INVESTMENT MANAGEMENT LLC | 67.7K -11.1K (-14.1%) | 5.35M -432.4K (-7.5%) | 0.12% -0.019 pp | 0.01% -0.001 pp | USD50.18 +57.4% | 11 qtrs — |
| 96 | VESTAL POINT CAPITAL, LP | 66.0K +66.0K (+100.0%) | 5.21M +5.2M (+100.0%) | 0.11% +0.114 pp | 0.18% +0.177 pp | USD78.99 +0.0% | 1 qtrs NEW |
| 97 | INVESCO LTD. | 65.0K -36.5K (-36.0%) | 5.13M -2.3M (-31.0%) | 0.11% -0.063 pp | 0.00% 0.000 pp | USD48.47 +63.0% | 22 qtrs — |
| 98 | CAPITAL FUND MANAGEMENT S.A. | 62.3K +26.2K (+72.5%) | 4.92M +2.3M (+85.9%) | 0.11% +0.045 pp | 0.01% +0.007 pp | USD61.07 +29.3% | 5 qtrs — |
| 99 | TCG CROSSOVER MANAGEMENT, LLC | 62.0K +62.0K (+100.0%) | 4.90M +4.9M (+100.0%) | 0.11% +0.107 pp | 0.16% +0.162 pp | USD78.99 +0.0% | 1 qtrs NEW |
| 100 | UBS ASSET MANAGEMENT AMERICAS INC | 59.2K -1.5K (-2.5%) | 4.68M +226.4K (+5.1%) | 0.10% -0.003 pp | 0.00% +0.000 pp | USD38.74 +103.9% | 13 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.50
Neutral
Ratio by volume
0.50
Neutral
Buys
1
Sells
2
Shares acquired
2.0K
Shares disposed
4.0K
Cash buys
—
Cash sales
1.00
Net activity
-2,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-15 | Ramasastry Saira | Director | M-Exempt | A | Common Stock | 2,000 | 23.51 | 47.0K | 2,000 | D | ↗ |
| 2026-03-16 | Ramasastry Saira | Director | S-Sale | D | Common Stock | 2,000 | 90.76 | 181.5K | 0 | D | ↗ |
| 2026-03-16 | Radovich Peter | Officer | S-Sale | D | Common Stock | 16,515 | 91.98 | 1.52M | 40,272 | D | ↗ |
| 2026-03-16 | Quan Joanne | Officer | S-Sale | D | Common Stock | 7,287 | 91.98 | 670.2K | 18,864 | D | ↗ |
| 2026-03-16 | Peetz Christopher | Director / Officer | S-Sale | D | Common Stock | 40,985 | 91.98 | 3.77M | 194,309 | D | ↗ |
| 2026-03-16 | Howe Jolanda | Officer | S-Sale | D | Common Stock | 4,732 | 91.98 | 435.2K | 8,429 | D | ↗ |
| 2026-03-16 | BJERKHOLT ERIC | Officer | S-Sale | D | Common Stock | 7,287 | 91.98 | 670.2K | 49,788 | D | ↗ |
| 2026-03-15 | Radovich Peter | Officer | M-Exempt | D | Performance Restricted Stock Units | 7,220 | 0.00 | — | 0 | D | ↗ |
| 2026-03-15 | Quan Joanne | Officer | M-Exempt | D | Performance Restricted Stock Units | 13,334 | 0.00 | — | 6,666 | D | ↗ |
| 2026-03-15 | Peetz Christopher | Director / Officer | M-Exempt | A | Common Stock | 25,000 | 0.00 | — | 185,294 | D | ↗ |
| 2026-03-15 | Howe Jolanda | Officer | M-Exempt | D | Performance Restricted Stock Units | 2,658 | 0.00 | — | 0 | D | ↗ |
| 2026-03-15 | BJERKHOLT ERIC | Officer | M-Exempt | D | Performance Restricted Stock Units | 13,334 | 0.00 | — | 6,666 | D | ↗ |
| 2026-03-06 | Radovich Peter | Officer | M-Exempt | D | Stock Option (right to buy) | 5,912 | 15.87 | 93.8K | 54,088 | D | ↗ |
| 2026-02-13 | Ramasastry Saira | Director | M-Exempt | D | Stock Option (right to buy) | 2,000 | 23.51 | 47.0K | 6,000 | D | ↗ |
| 2026-02-02 | Radovich Peter | Officer | S-Sale | D | Common Stock | 2,631 | 103.30 | 271.8K | 20,655 | D | ↗ |
| 2026-02-02 | Peetz Christopher | Director / Officer | S-Sale | D | Common Stock | 9,108 | 103.30 | 940.9K | 160,294 | D | ↗ |
| 2026-02-02 | Howe Jolanda | Officer | S-Sale | D | Common Stock | 968 | 103.30 | 100.0K | 4,503 | D | ↗ |
| 2026-01-31 | Howe Jolanda | Officer | M-Exempt | D | Restricted Stock Units | 1,771 | 0.00 | — | 0 | D | ↗ |
| 2026-01-28 | Radovich Peter | Officer | A-Award | A | Restricted Stock Units | 16,280 | 0.00 | — | 16,280 | D | ↗ |
| 2026-01-28 | Quan Joanne | Officer | A-Award | A | Restricted Stock Units | 11,760 | 0.00 | — | 11,760 | D | ↗ |
| 2026-01-28 | Peetz Christopher | Director / Officer | A-Award | A | Restricted Stock Units | 43,500 | 0.00 | — | 43,500 | D | ↗ |
| 2026-01-28 | Howe Jolanda | Officer | A-Award | A | Restricted Stock Units | 4,970 | 0.00 | — | 4,970 | D | ↗ |
| 2026-01-28 | BJERKHOLT ERIC | Officer | A-Award | A | Stock Option (right to buy) | 18,140 | 100.85 | 1.83M | 18,140 | D | ↗ |
| 2026-01-26 | Radovich Peter | Officer | S-Sale | D | Common Stock | 3,143 | 96.19 | 302.3K | 23,286 | D | ↗ |
| 2026-01-26 | Peetz Christopher | Director / Officer | S-Sale | D | Common Stock | 6,831 | 96.19 | 657.1K | 169,402 | D | ↗ |
| 2026-01-26 | Howe Jolanda | Officer | S-Sale | D | Common Stock | 842 | 96.19 | 81.0K | 3,700 | D | ↗ |
| 2026-01-26 | BJERKHOLT ERIC | Officer | S-Sale | D | Common Stock | 1,053 | 96.19 | 101.3K | 43,741 | D | ↗ |
| 2026-01-23 | Radovich Peter | Officer | M-Exempt | D | Restricted Stock Units | 5,750 | 0.00 | — | 5,750 | D | ↗ |
| 2026-01-23 | Peetz Christopher | Director / Officer | M-Exempt | D | Restricted Stock Units | 12,500 | 0.00 | — | 12,500 | D | ↗ |
| 2026-01-23 | Howe Jolanda | Officer | M-Exempt | D | Restricted Stock Units | 1,500 | 0.00 | — | 1,500 | D | ↗ |
| 2026-01-23 | Heron Patrick J | Director | J-Other | A | Common Stock | 159,277 | 94.29 | 15.02M | 327,585 | I | ↗ |
| 2026-01-23 | BJERKHOLT ERIC | Officer | M-Exempt | D | Restricted Stock Units | 2,667 | 0.00 | — | 2,666 | D | ↗ |
| 2026-01-22 | Radovich Peter | Officer | S-Sale | D | Common Stock | 2,382 | 93.33 | 222.3K | 20,679 | D | ↗ |
| 2026-01-22 | Quan Joanne | Officer | S-Sale | D | Common Stock | 1,822 | 93.33 | 170.0K | 12,817 | D | ↗ |
| 2026-01-22 | Peetz Christopher | Director / Officer | S-Sale | D | Common Stock | 7,098 | 93.33 | 662.4K | 163,733 | D | ↗ |
| 2026-01-22 | Howe Jolanda | Officer | S-Sale | D | Common Stock | 926 | 93.33 | 86.4K | 3,042 | D | ↗ |
| 2026-01-22 | BJERKHOLT ERIC | Officer | S-Sale | D | Common Stock | 1,421 | 93.33 | 132.6K | 42,127 | D | ↗ |
| 2026-01-21 | Radovich Peter | Officer | M-Exempt | A | Common Stock | 4,167 | 0.00 | — | 23,061 | D | ↗ |
| 2026-01-21 | Quan Joanne | Officer | M-Exempt | D | Restricted Stock Units | 3,334 | 0.00 | — | 6,666 | D | ↗ |
| 2026-01-21 | Peetz Christopher | Director / Officer | M-Exempt | D | Restricted Stock Units | 12,797 | 0.00 | — | 25,593 | D | ↗ |
| 2026-01-21 | Howe Jolanda | Officer | M-Exempt | D | Restricted Stock Units | 1,542 | 0.00 | — | 3,083 | D | ↗ |
| 2026-01-21 | BJERKHOLT ERIC | Officer | M-Exempt | D | Restricted Stock Units | 3,334 | 0.00 | — | 6,666 | D | ↗ |
| 2026-01-20 | Quan Joanne | Officer | S-Sale | D | Common Stock | 6,911 | 90.27 | 623.9K | 11,305 | D | ↗ |
| 2026-01-16 | Quan Joanne | Officer | M-Exempt | A | Common Stock | 12,500 | 0.00 | — | 18,216 | D | ↗ |
| 2026-01-15 | Ramasastry Saira | Director | M-Exempt | D | Stock Option (right to buy) | 2,000 | 23.51 | 47.0K | 8,000 | D | ↗ |
| 2025-12-31 | Peetz Christopher | Director / Officer | G-Gift | D | Common Stock | 21,070 | 0.00 | — | 187,500 | I | ↗ |
| 2025-12-22 | Ramasastry Saira | Director | S-Sale | D | Common Stock | 5,000 | 80.00 | 400.0K | 0 | D | ↗ |
| 2025-12-19 | GREY MICHAEL G | Director | S-Sale | D | Common Stock | 50,000 | 78.00 | 3.90M | 0 | D | ↗ |
| 2025-12-18 | Ramasastry Saira | Director | M-Exempt | D | Stock Option (right to buy) | 2,000 | 23.51 | 47.0K | 15,000 | D | ↗ |
| 2025-12-01 | GREY MICHAEL G | Director | M-Exempt | D | Stock Option (right to buy) | 50,000 | 2.94 | 146.8K | 231,176 | D | ↗ |
| 2025-11-21 | GREY MICHAEL G | Director | M-Exempt | D | Stock Option (right to buy) | 50,000 | 2.94 | 146.8K | 281,176 | D | ↗ |
| 2025-11-18 | Peetz Christopher | Director / Officer | M-Exempt | A | Common Stock | 19,133 | 19.24 | 368.1K | 158,034 | D | ↗ |
| 2025-09-12 | BJERKHOLT ERIC | Officer | S-Sale | D | Common Stock | 9,578 | 76.01 | 728.0K | 39,945 | D | ↗ |
| 2025-09-11 | Brege Laura | Director | M-Exempt | D | Stock Option (right to buy) | 17,000 | 15.00 | 255.0K | 0 | D | ↗ |
| 2025-09-11 | BJERKHOLT ERIC | Officer | M-Exempt | D | Restricted Stock Units | 18,333 | 0.00 | — | 18,333 | D | ↗ |
| 2025-09-08 | Ramasastry Saira | Director | M-Exempt | D | Stock Option (right to buy) | 17,000 | 23.51 | 399.7K | 17,000 | D | ↗ |
| 2025-08-12 | BJERKHOLT ERIC | Officer | M-Exempt | A | Common Stock | 2,954 | 26.49 | 78.3K | 31,190 | D | ↗ |
| 2025-08-11 | Peetz Christopher | Director / Officer | M-Exempt | A | Common Stock | 40,000 | 2.94 | 117.4K | 178,641 | D | ↗ |
| 2025-08-11 | BJERKHOLT ERIC | Officer | S-Sale | D | Common Stock | 8,000 | 0.00 | — | 28,236 | D | ↗ |
| 2025-08-07 | Peetz Christopher | Director / Officer | M-Exempt | A | Common Stock | 40,000 | 2.94 | 117.4K | 178,641 | D | ↗ |
| 2025-08-07 | Howe Jolanda | Officer | S-Sale | D | Common Stock | 10,000 | 58.00 | 580.0K | 2,426 | D | ↗ |
| 2025-07-03 | Howe Jolanda | Officer | S-Sale | D | Common Stock | 477 | 49.08 | 23.4K | 2,426 | D | ↗ |
| 2025-07-02 | Howe Jolanda | Officer | S-Sale | D | Common Stock | 564 | 48.25 | 27.2K | 2,903 | D | ↗ |
| 2025-07-01 | Howe Jolanda | Officer | M-Exempt | A | Common Stock | 1,041 | 0.00 | — | 3,467 | D | ↗ |
| 2025-06-11 | Fairey William | Director | S-Sale | D | Common Stock | 3,203 | 48.42 | 155.1K | 2,500 | D | ↗ |
| 2025-06-03 | Ramasastry Saira | Director | M-Exempt | A | Common Stock | 2,500 | 14.12 | 35.3K | 2,500 | D | ↗ |
| 2025-06-02 | Ramasastry Saira | Director | S-Sale | D | Common Stock | 5,703 | 46.20 | 263.5K | 0 | D | ↗ |
| 2025-05-29 | Walbert Timothy P | Director | M-Exempt | A | Common Stock | 5,703 | 0.00 | — | 5,703 | D | ↗ |
| 2025-05-29 | Ramasastry Saira | Director | A-Award | A | Stock Option (right to buy) | 6,268 | 44.00 | 275.8K | 6,268 | D | ↗ |
| 2025-05-29 | Heron Patrick J | Director | M-Exempt | A | Common Stock | 5,703 | 0.00 | — | 5,703 | D | ↗ |
| 2025-05-29 | GREY MICHAEL G | Director | A-Award | A | Stock Option (right to buy) | 6,268 | 44.00 | 275.8K | 6,268 | D | ↗ |
| 2025-05-29 | Fischer Laurent | Director | A-Award | A | Stock Option (right to buy) | 6,268 | 44.00 | 275.8K | 6,268 | D | ↗ |
| 2025-05-29 | Fairey William | Director | M-Exempt | D | Restricted Stock Units | 5,703 | 0.00 | — | 0 | D | ↗ |
| 2025-05-29 | Cardon Lon | Director | A-Award | A | Stock Option (right to buy) | 6,268 | 44.00 | 275.8K | 6,268 | D | ↗ |
| 2025-05-29 | Brege Laura | Director | M-Exempt | D | Restricted Stock Units | 5,703 | 0.00 | — | 0 | D | ↗ |
| 2025-03-18 | Howe Jolanda | Officer | S-Sale | D | Common Stock | 2,415 | 44.45 | 107.3K | 2,426 | D | ↗ |
| 2025-03-17 | Radovich Peter | Officer | S-Sale | D | Common Stock | 7,879 | 44.21 | 348.4K | 18,672 | D | ↗ |
| 2025-03-17 | Peetz Christopher | Director / Officer | S-Sale | D | Common Stock | 27,279 | 44.21 | 1.21M | 138,641 | D | ↗ |
| 2025-03-17 | Howe Jolanda | Officer | S-Sale | D | Common Stock | 2,789 | 44.75 | 124.8K | 6,647 | D | ↗ |
| 2025-03-17 | Heron Patrick J | Director | P-Purchase | A | Common Stock | 21 | 43.93 | 922.61 | 168,672 | I | ↗ |
| 2025-03-15 | Radovich Peter | Officer | M-Exempt | D | Performance Restricted Stock Units | 14,440 | 0.00 | — | 7,220 | D | ↗ |
| 2025-03-15 | Peetz Christopher | Director / Officer | M-Exempt | A | Common Stock | 50,000 | 0.00 | — | 165,920 | D | ↗ |
| 2025-03-15 | Howe Jolanda | Officer | M-Exempt | D | Performance Restricted Stock Units | 5,315 | 0.00 | — | 2,658 | D | ↗ |
| 2025-03-14 | Heron Patrick J | Director | P-Purchase | A | Common Stock | 528 | 44.11 | 23.3K | 168,651 | I | ↗ |
| 2025-03-11 | Heron Patrick J | Director | P-Purchase | A | Common Stock | 963 | 43.77 | 42.2K | 168,123 | I | ↗ |
| 2025-03-10 | Heron Patrick J | Director | P-Purchase | A | Common Stock | 577 | 43.37 | 25.0K | 167,160 | I | ↗ |
| 2025-03-07 | Heron Patrick J | Director | P-Purchase | A | Common Stock | 580 | 43.21 | 25.1K | 165,825 | I | ↗ |
| 2025-03-06 | Heron Patrick J | Director | P-Purchase | A | Common Stock | 1,335 | 43.89 | 58.6K | 165,245 | I | ↗ |
| 2025-03-05 | Heron Patrick J | Director | P-Purchase | A | Common Stock | 267 | 44.55 | 11.9K | 163,910 | I | ↗ |
| 2025-03-04 | Radovich Peter | Officer | S-Sale | D | Common Stock | 13,681 | 45.57 | 623.5K | 13,280 | D | ↗ |
| 2025-03-04 | Heron Patrick J | Director | P-Purchase | A | Common Stock | 56 | 45.96 | 2.6K | 163,643 | I | ↗ |
| 2025-03-03 | Peetz Christopher | Director / Officer | S-Sale | D | Common Stock | 20,608 | 47.19 | 972.5K | 115,920 | D | ↗ |
| 2025-02-03 | Radovich Peter | Officer | S-Sale | D | Common Stock | 2,627 | 48.22 | 126.7K | 26,961 | D | ↗ |
| 2025-02-03 | Peetz Christopher | Director / Officer | S-Sale | D | Common Stock | 9,102 | 48.22 | 438.9K | 115,920 | D | ↗ |
| 2025-02-03 | Howe Jolanda | Officer | S-Sale | D | Common Stock | 1,064 | 48.22 | 51.3K | 4,232 | D | ↗ |
| 2025-01-31 | Howe Jolanda | Officer | M-Exempt | A | Common Stock | 1,772 | 0.00 | — | 5,296 | D | ↗ |
| 2025-01-24 | Radovich Peter | Officer | S-Sale | D | Common Stock | 3,177 | 47.92 | 152.3K | 29,588 | D | ↗ |
| 2025-01-24 | Peetz Christopher | Director / Officer | S-Sale | D | Common Stock | 6,837 | 47.92 | 327.7K | 125,022 | D | ↗ |
| 2025-01-24 | Howe Jolanda | Officer | S-Sale | D | Common Stock | 902 | 47.92 | 43.2K | 3,524 | D | ↗ |
| 2025-01-23 | Radovich Peter | Officer | M-Exempt | D | Restricted Stock Units | 5,750 | 0.00 | — | 11,500 | D | ↗ |
| 2025-01-23 | Peetz Christopher | Director / Officer | M-Exempt | D | Restricted Stock Units | 12,500 | 0.00 | — | 25,000 | D | ↗ |
| 2025-01-23 | Howe Jolanda | Officer | M-Exempt | D | Restricted Stock Units | 1,500 | 0.00 | — | 3,000 | D | ↗ |
| 2025-01-23 | BJERKHOLT ERIC | Officer | M-Exempt | D | Restricted Stock Units | 2,667 | 0.00 | — | 5,333 | D | ↗ |
| 2025-01-21 | Radovich Peter | Officer | A-Award | A | Restricted Stock Units | 12,500 | 0.00 | — | 12,500 | D | ↗ |
| 2025-01-21 | Quan Joanne | Officer | A-Award | A | Stock Option (right to buy) | 40,000 | 47.98 | 1.92M | 40,000 | D | ↗ |
| 2025-01-21 | Peetz Christopher | Director / Officer | A-Award | A | Restricted Stock Units | 38,390 | 0.00 | — | 38,390 | D | ↗ |
| 2025-01-21 | Howe Jolanda | Officer | A-Award | A | Stock Option (right to buy) | 18,500 | 47.98 | 887.6K | 18,500 | D | ↗ |
| 2025-01-21 | BJERKHOLT ERIC | Officer | A-Award | A | Restricted Stock Units | 10,000 | 0.00 | — | 10,000 | D | ↗ |
| 2025-01-17 | Quan Joanne | Officer | S-Sale | D | Common Stock | 6,969 | 45.86 | 319.6K | 5,649 | D | ↗ |
| 2025-01-16 | Quan Joanne | Officer | M-Exempt | D | Restricted Stock Units | 12,500 | 0.00 | — | 25,000 | D | ↗ |
| 2025-01-07 | Radovich Peter | Officer | S-Sale | D | Common Stock | 1,998 | 42.82 | 85.5K | 27,015 | D | ↗ |
| 2025-01-07 | Peetz Christopher | Director / Officer | S-Sale | D | Common Stock | 7,489 | 42.82 | 320.6K | 119,359 | D | ↗ |
| 2025-01-07 | Howe Jolanda | Officer | S-Sale | D | Common Stock | 750 | 42.82 | 32.1K | 2,926 | D | ↗ |
| 2025-01-06 | Howe Jolanda | Officer | M-Exempt | A | Common Stock | 1,250 | 0.00 | — | 3,676 | D | ↗ |
| 2024-11-14 | Howe Jolanda | Officer | M-Exempt | D | Stock Option (right to buy) | 2,500 | 2.94 | 7.4K | 52,900 | D | ↗ |
| 2024-11-08 | Quan Joanne | Officer | A-Award | A | Common Stock | 118 | 21.05 | 2.5K | 118 | D | ↗ |
| 2024-11-08 | Peetz Christopher | Director / Officer | A-Award | A | Common Stock | 65 | 21.05 | 1.4K | 126,848 | D | ↗ |
| 2024-11-08 | BJERKHOLT ERIC | Officer | A-Award | A | Common Stock | 475 | 21.05 | 10.0K | 33,279 | D | ↗ |
| 2024-09-27 | GREY MICHAEL G | Director | G-Gift | D | Common Stock | 102,788 | 0.00 | — | 186,410 | I | ↗ |
| 2024-09-18 | Heron Patrick J | Director | P-Purchase | A | Common Stock | 115 | 37.40 | 4.3K | 162,308 | I | ↗ |
| 2024-09-11 | BJERKHOLT ERIC | Officer | M-Exempt | D | Restricted Stock Units | 18,334 | 0.00 | — | 36,666 | — | ↗ |
| 2024-09-06 | Heron Patrick J | Director | P-Purchase | A | Common Stock | 230 | 41.58 | 9.6K | 162,193 | — | ↗ |
| 2024-07-23 | Peetz Christopher | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 34,013 | 2.94 | 99.9K | 278,487 | — | ↗ |
| 2024-07-02 | Howe Jolanda | Officer | S-Sale | D | Common Stock | 375 | 34.00 | 12.8K | 2,426 | — | ↗ |
| 2024-07-01 | Howe Jolanda | Officer | M-Exempt | A | Common Stock | 1,042 | 0.00 | — | 2,801 | — | ↗ |
| 2024-06-24 | Vig Pamela | Officer | M-Exempt | A | Common Stock | 30,559 | 2.94 | 89.7K | 57,965 | — | ↗ |
| 2024-06-05 | Walbert Timothy P | Director | A-Award | A | Restricted Stock Units | 5,703 | 0.00 | — | 5,703 | — | ↗ |
| 2024-06-05 | Ramasastry Saira | Director | S-Sale | D | Common Stock | 5,000 | 25.68 | 128.4K | 0 | — | ↗ |
| 2024-06-05 | Heron Patrick J | Director | A-Award | A | Restricted Stock Units | 5,703 | 0.00 | — | 5,703 | — | ↗ |
| 2024-06-05 | GREY MICHAEL G | Director | A-Award | A | Deferred Stock Units | 5,703 | 0.00 | — | 5,703 | — | ↗ |
| 2024-06-05 | Fischer Laurent | Director | A-Award | A | Deferred Stock Units | 5,703 | 0.00 | — | 5,703 | — | ↗ |
| 2024-06-05 | Fairey William | Director | A-Award | A | Restricted Stock Units | 5,703 | 0.00 | — | 5,703 | — | ↗ |
| 2024-06-05 | Cardon Lon | Director | A-Award | A | Restricted Stock Units | 5,703 | 0.00 | — | 5,703 | — | ↗ |
| 2024-06-05 | Brege Laura | Director | A-Award | A | Restricted Stock Units | 5,703 | 0.00 | — | 5,703 | — | ↗ |
| 2024-05-10 | Vig Pamela | Officer | A-Award | A | Common Stock | 94 | 21.05 | 2.0K | 27,406 | — | ↗ |
| 2024-05-10 | Peetz Christopher | Director / Officer | A-Award | A | Common Stock | 817 | 21.05 | 17.2K | 92,770 | — | ↗ |
| 2024-05-10 | BJERKHOLT ERIC | Officer | A-Award | A | Common Stock | 470 | 21.05 | 9.9K | 14,470 | — | ↗ |
| 2024-03-27 | BJERKHOLT ERIC | Officer | P-Purchase | A | Common Stock | 2,000 | 24.80 | 49.6K | 14,000 | — | ↗ |
| 2024-03-25 | Radovich Peter | Officer | S-Sale | D | Common Stock | 4,303 | 25.80 | 111.0K | 29,013 | — | ↗ |
| 2024-03-18 | BJERKHOLT ERIC | Officer | P-Purchase | A | Common Stock | 2,000 | 25.80 | 51.6K | 12,000 | — | ↗ |
| 2024-02-02 | Vig Pamela | Officer | S-Sale | D | Common Stock | 1,214 | 26.19 | 31.8K | 28,691 | — | ↗ |
| 2024-02-02 | Radovich Peter | Officer | S-Sale | D | Common Stock | 1,790 | 26.19 | 46.9K | 34,695 | — | ↗ |
| 2024-02-02 | Peetz Christopher | Director / Officer | S-Sale | D | Common Stock | 6,013 | 26.19 | 157.5K | 104,112 | — | ↗ |
| 2024-02-02 | Longpre Lara | Officer | S-Sale | D | Common Stock | 847 | 26.19 | 22.2K | 104,407 | — | ↗ |
| 2024-02-02 | Howe Jolanda | Officer | S-Sale | D | Common Stock | 735 | 26.19 | 19.3K | 1,759 | — | ↗ |
| 2024-01-31 | Howe Jolanda | Officer | M-Exempt | D | Restricted Stock Units | 1,772 | 0.00 | — | 3,543 | — | ↗ |
| 2024-01-23 | Vig Pamela | Officer | A-Award | A | Restricted Stock Units | 8,000 | 0.00 | — | 8,000 | — | ↗ |
| 2024-01-23 | Radovich Peter | Officer | A-Award | A | Restricted Stock Units | 17,250 | 0.00 | — | 17,250 | — | ↗ |
| 2024-01-23 | Peetz Christopher | Director / Officer | A-Award | A | Restricted Stock Units | 37,500 | 0.00 | — | 37,500 | — | ↗ |
| 2024-01-23 | Longpre Lara | Officer | A-Award | A | Restricted Stock Units | 8,000 | 0.00 | — | 8,000 | — | ↗ |
| 2024-01-23 | Howe Jolanda | Officer | A-Award | A | Stock Option (right to buy) | 18,000 | 26.49 | 476.8K | 18,000 | — | ↗ |
| 2024-01-23 | BJERKHOLT ERIC | Officer | A-Award | A | Restricted Stock Units | 8,000 | 0.00 | — | 8,000 | — | ↗ |
| 2024-01-16 | Quan Joanne | Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 26.72 | 2.00M | 75,000 | — | ↗ |
| 2024-01-08 | Vig Pamela | Officer | S-Sale | D | Common Stock | 1,408 | 28.03 | 39.5K | 29,905 | — | ↗ |
| 2024-01-08 | Radovich Peter | Officer | S-Sale | D | Common Stock | 1,408 | 28.03 | 39.5K | 36,485 | — | ↗ |
| 2024-01-08 | Peetz Christopher | Director / Officer | S-Sale | D | Common Stock | 5,209 | 28.03 | 146.0K | 110,125 | — | ↗ |
| 2024-01-08 | Longpre Lara | Officer | S-Sale | D | Common Stock | 1,019 | 28.04 | 28.6K | 105,254 | — | ↗ |
| 2024-01-08 | Howe Jolanda | Officer | S-Sale | D | Common Stock | 528 | 28.04 | 14.8K | 722 | — | ↗ |
| 2024-01-06 | Howe Jolanda | Officer | M-Exempt | D | Restricted Stock Units | 1,250 | 0.00 | — | 1,250 | — | ↗ |
| 2023-12-05 | Howe Jolanda | Officer | M-Exempt | D | Stock Option (right to buy) | 2,500 | 2.94 | 7.4K | 55,400 | — | ↗ |
| 2023-11-10 | Vig Pamela | Officer | A-Award | A | Common Stock | 527 | 22.29 | 11.7K | 31,313 | — | ↗ |
| 2023-11-10 | Radovich Peter | Officer | A-Award | A | Common Stock | 218 | 22.29 | 4.9K | 37,893 | — | ↗ |
| 2023-11-10 | Longpre Lara | Officer | A-Award | A | Common Stock | 434 | 22.29 | 9.7K | 106,273 | — | ↗ |
| 2023-11-09 | Heron Patrick J | Director | P-Purchase | A | Common Stock | 2,910 | 28.30 | 82.4K | 161,963 | — | ↗ |
| 2023-09-14 | GREY MICHAEL G | Director | M-Exempt | D | Stock Option (right to buy) | 14,216 | 2.94 | 41.7K | 331,176 | — | ↗ |
| 2023-09-13 | Heron Patrick J | Director | P-Purchase | A | Common Stock | 2,625 | 31.02 | 81.4K | 159,053 | — | ↗ |
| 2023-09-13 | GREY MICHAEL G | Director | M-Exempt | D | Stock Option (right to buy) | 392 | 2.94 | 1.2K | 345,392 | — | ↗ |
| 2023-09-12 | Heron Patrick J | Director | P-Purchase | A | Common Stock | 3,750 | 30.60 | 114.8K | 156,428 | — | ↗ |
| 2023-09-11 | Heron Patrick J | Director | P-Purchase | A | Common Stock | 4,687 | 30.30 | 142.0K | 152,678 | — | ↗ |
| 2023-09-11 | BJERKHOLT ERIC | Officer | A-Award | A | Stock Option (right to buy) | 110,000 | 30.43 | 3.35M | 110,000 | — | ↗ |
| 2023-08-31 | Heron Patrick J | Director / 10% Owner | P-Purchase | A | Common Stock | 147,991 | 26.25 | 3.88M | 147,991 | — | ↗ |
| 2023-08-25 | Howe Jolanda | Officer | S-Sale | D | Common Stock | 3,459 | 26.23 | 90.7K | 0 | — | ↗ |
| 2023-07-03 | Vig Pamela | Officer | S-Sale | D | Common Stock | 1,425 | 25.65 | 36.5K | 30,786 | — | ↗ |
| 2023-07-03 | Radovich Peter | Officer | S-Sale | D | Common Stock | 1,425 | 25.65 | 36.5K | 37,675 | — | ↗ |
| 2023-07-03 | Peetz Christopher | Director / Officer | S-Sale | D | Common Stock | 5,498 | 25.65 | 141.0K | 115,334 | — | ↗ |
| 2023-07-03 | Longpre Lara | Officer | S-Sale | D | Common Stock | 1,004 | 25.65 | 25.7K | 105,839 | — | ↗ |
| 2023-07-03 | Howe Jolanda | Officer | S-Sale | D | Common Stock | 915 | 25.65 | 23.5K | 3,459 | — | ↗ |
| 2023-07-01 | Howe Jolanda | Officer | M-Exempt | D | Restricted Stock Units | 1,042 | 0.00 | — | 2,083 | — | ↗ |
| 2023-06-30 | Howe Jolanda | Officer | M-Exempt | A | Common Stock | 1,563 | 0.00 | — | 3,332 | — | ↗ |
| 2023-06-13 | Walker Paul Edward | 10% Owner | J-Other | D | Common Stock | 2,000,000 | 0.00 | — | 2,186,243 | — | ↗ |
| 2023-06-13 | SANDELL SCOTT D | 10% Owner | J-Other | A | Common Stock | 1,455 | 0.00 | — | 1,455 | — | ↗ |
| 2023-06-13 | New Enterprise Associates 16, L.P. | 10% Owner | J-Other | D | Common Stock | 2,000,000 | 0.00 | — | 2,186,243 | — | ↗ |
| 2023-06-13 | NEA Partners 16, L.P. | 10% Owner | J-Other | A | Common Stock | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2023-06-13 | Makhzoumi Mohamad | 10% Owner | J-Other | D | Common Stock | 2,000,000 | 0.00 | — | 2,186,243 | — | ↗ |
| 2023-06-13 | Florence Anthony A. Jr. | 10% Owner | J-Other | D | Common Stock | 30,000 | 0.00 | — | 0 | — | ↗ |
| 2023-06-13 | Chang Carmen | 10% Owner | J-Other | D | Common Stock | 2,000,000 | 0.00 | — | 2,186,243 | — | ↗ |
| 2023-06-13 | Behbahani Ali | 10% Owner | J-Other | D | Common Stock | 30,000 | 0.00 | — | 0 | — | ↗ |
| 2023-06-13 | BASKETT FOREST | 10% Owner | J-Other | D | Common Stock | 2,000,000 | 0.00 | — | 2,186,243 | — | ↗ |
| 2023-06-12 | Walbert Timothy P | Director | A-Award | A | Stock Option (right to buy) | 1,417 | 28.97 | 41.1K | 1,417 | — | ↗ |
| 2023-06-12 | Ramasastry Saira | Director | A-Award | A | Stock Option (right to buy) | 17,000 | 28.97 | 492.5K | 17,000 | — | ↗ |
| 2023-06-12 | Heron Patrick J | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 17,000 | 28.97 | 492.5K | 17,000 | — | ↗ |
| 2023-06-12 | GREY MICHAEL G | Director | A-Award | A | Stock Option (right to buy) | 17,000 | 28.97 | 492.5K | 17,000 | — | ↗ |
| 2023-06-12 | Fischer Laurent | Director | A-Award | A | Stock Option (right to buy) | 17,000 | 28.97 | 492.5K | 17,000 | — | ↗ |
| 2023-06-12 | Fairey William | Director | A-Award | A | Stock Option (right to buy) | 17,000 | 28.97 | 492.5K | 17,000 | — | ↗ |
| 2023-06-12 | Cardon Lon | Director | A-Award | A | Stock Option (right to buy) | 7,083 | 28.97 | 205.2K | 7,083 | — | ↗ |
| 2023-06-12 | Brege Laura | Director | A-Award | A | Stock Option (right to buy) | 17,000 | 28.97 | 492.5K | 17,000 | — | ↗ |
| 2023-06-08 | GREY MICHAEL G | Director | M-Exempt | D | Stock Option (right to buy) | 14,608 | 2.94 | 42.9K | 345,784 | — | ↗ |
| 2023-05-10 | Vig Pamela | Officer | A-Award | A | Common Stock | 684 | 16.92 | 11.6K | 32,211 | — | ↗ |
| 2023-05-10 | Radovich Peter | Officer | A-Award | A | Common Stock | 968 | 16.92 | 16.4K | 39,100 | — | ↗ |
| 2023-05-10 | Peetz Christopher | Director / Officer | A-Award | A | Common Stock | 1,256 | 16.92 | 21.3K | 120,832 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-21.1K
Shares Outstanding
50.20M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Christopher Peetz Chief Executive Officer | 755.0K | — | 3.68M | 4.93M | 1.06M | 14.0K | 10.44M | 82.51% | ↗ |
| 2 | 2025 | Peter Radovich President and Chief Operating Officer | 572.5K | — | 1.20M | 1.61M | 572.5K | 14.0K | 3.96M | 70.76% | ↗ |
| 3 | 2025 | Eric Bjerkholt Chief Financial Officer | 520.0K | — | 959.6K | 1.28M | 468.0K | 14.0K | 3.25M | 69.13% | ↗ |
| 4 | 2025 | Joanne Quan, M.D. Chief Medical Officer | 520.0K | — | 959.6K | 1.28M | 468.0K | 14.0K | 3.25M | 69.13% | ↗ |
| 5 | 2024 | Christopher Peetz Chief Executive Officer | 730.0K | — | 2.22M | 2.84M | 792.1K | 13.8K | 6.60M | 76.72% | ↗ |
| 6 | 2024 | Joanne Quan, M.D. Chief Medical Officer | 479.2K | — | 1.33M | 1.43M | 334.5K | 13.8K | 3.59M | 76.95% | ↗ |
| 7 | 2024 | Peter Radovich President and Chief Operating Officer | 550.0K | — | 1.02M | 1.33M | 426.3K | 13.8K | 3.34M | 70.34% | ↗ |
| 8 | 2024 | Eric Bjerkholt Chief Financial Officer | 500.0K | — | 538.5K | 606.8K | 348.8K | 12.1K | 2.01M | 57.09% | ↗ |
| 9 | 2023 | Christopher Peetz Chief Executive Officer | 660.0K | — | 1.76M | 3.38M | 633.6K | 13.2K | 6.45M | 79.74% | ↗ |
| 10 | 2023 | Eric Bjerkholt Chief Financial Officer | 151.6K | — | 1.67M | 2.42M | 95.2K | — | 4.34M | 94.31% | ↗ |
| 11 | 2023 | Peter Radovich President and Chief Operating Officer | 505.0K | — | 508.6K | 977.1K | 363.6K | 13.2K | 2.37M | 62.75% | ↗ |
| 12 | 2023 | Joanne Quan, M.D. Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 13 | 2022 | Christopher Peetz President and Chief Executive Officer | 624.0K | — | 634.8K | 2.68M | 449.3K | 12.2K | 4.40M | 75.34% | ↗ |
| 14 | 2022 | Christopher Peetz Chief Executive Officer | 624.0K | — | 634.8K | 2.68M | 449.3K | 12.2K | 4.40M | 75.34% | ↗ |
| 15 | 2022 | Peter Radovich President and Chief Operating Officer | 467.5K | — | 158.7K | 670.6K | 252.5K | 12.2K | 1.56M | 53.11% | ↗ |
| 16 | 2022 | Peter Radovich Chief Operating Officer | 467.5K | — | 158.7K | 670.6K | 252.5K | 12.2K | 1.56M | 53.11% | ↗ |
| 17 | 2022 | Pamela Vig, Ph.D. Head of Research and Development | 450.0K | — | 158.7K | 670.6K | 216.0K | 12.2K | 1.51M | 55.01% | ↗ |
| 18 | 2022 | Lara Longpre Chief Development Officer | 450.0K | — | 158.7K | 670.6K | 216.0K | 12.2K | 1.51M | 55.01% | ↗ |
| 19 | 2021 | Christopher Peetz President and Chief Executive Officer | 600.0K | — | 559.8K | 2.55M | 412.5K | 11.6K | 4.13M | 75.21% | ↗ |
| 20 | 2021 | Ian Clements Ph.D. Chief Financial Officer | 425.0K | — | 239.9K | 1.09M | 212.5K | 11.6K | 1.98M | 67.23% | ↗ |
| 21 | 2021 | Edwin Tucker M.D. Former Chief Medical Officer | 383.1K | — | 207.9K | 946.0K | — | 418.7K | 1.96M | 59.00% | ↗ |
| 22 | 2021 | Peter Radovich Chief Operating Officer | 425.0K | — | 207.9K | 946.0K | 212.5K | 11.6K | 1.80M | 64.00% | ↗ |
| 23 | 2020 | Christopher Peetz President and Chief Executive Officer | 511.8K | — | — | 2.22M | 266.0K | 7.5K | 3.00M | 73.86% | ↗ |
| 24 | 2020 | Christopher Peetz Chief Executive Officer and President | 511.8K | 266.0K | — | 2.22M | — | 7.5K | 3.00M | 73.86% | ↗ |
| 25 | 2020 | Peter Radovich Chief Operating Officer | 278.0K | — | — | 2.26M | 111.2K | — | 2.64M | 85.28% | ↗ |
| 26 | 2020 | Ian Clements Ph.D. Chief Financial Officer | 378.4K | — | — | 848.3K | 151.4K | 11.4K | 1.39M | 61.05% | ↗ |
| 27 | 2020 | Ian Clements, Ph.D. Chief Financial Officer | 378.4K | 151.4K | — | 848.3K | — | 11.4K | 1.39M | 61.05% | ↗ |
| 28 | 2019 | Christopher Peetz Chief Executive Officer and President | 457.6K | 286.1K | — | 5.49M | — | — | 6.24M | 88.07% | ↗ |
| 29 | 2019 | Michael Grey Former Executive Chairman and Chief Executive Officer | 300.0K | 150.0K | — | 5.21M | — | — | 5.66M | 92.05% | ↗ |
| 30 | 2019 | Pamela Vig, Ph.D Chief Scientific Officer | 354.8K | 155.3K | — | 2.17M | — | — | 2.68M | 80.98% | ↗ |
| 31 | 2019 | Lara Longpre Chief Development Officer | 354.8K | 155.3K | — | 2.17M | — | — | 2.53M | 85.96% | ↗ |
| 32 | 2018 | Christopher Peetz Chief Executive Officer and President | 32.1K | — | — | — | — | — | 32.1K | 0.00% | ↗ |
| 33 | 2018 | Lara Longpre Chief Development Officer | 27.5K | — | — | — | — | — | 27.5K | 0.00% | ↗ |
| 34 | 2018 | Pamela Vig, Ph.D Chief Scientific Officer | 27.5K | — | — | — | — | — | 27.5K | 0.00% | ↗ |
| 35 | 2018 | Michael Grey Former Executive Chairman and Chief Executive Officer | 25.0K | — | — | — | — | — | 25.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Christopher Peetz | Chief Executive Officer & Director | 2M | male |
| Peter Radovich | Chief Operating Officer & President | 1M | male |
| Joanne J. Quan | Chief Medical Officer | 1M | — |
| Eric H. Bjerkholt | Chief Financial Officer | 1M | male |
| Lara Longpre | Chief Development Officer | 678.2K | female |
| Andrew McKibben | Senior Vice President, Strategic Finance & Investor Relations | — | male |
| Vinita Kumar | Senior Vice President of Quality | — | female |
| Douglas T. Sheehy | Chief Legal Officer & Secretary | — | male |
| Erin Campany | Chief People Officer | — | female |
| Jean-Luc Girardet | Chief Technical Officer | — | — |
| Meredith Kiernan | Senior Director of Global Corporate Communications | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MIRM
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
